Histogenics $49M Round to Advance NeoCart Implant
Regenerative medicine developer Histogenics Corp. said Tuesday that it completed a $49 million financing to complete its ongoing Phase III program for lead candidate NeoCart, an autologous neocartilage tissue implant that utilizes a patient's own cells to regenerate articular cartilage in the knee. The trial is currently enrolling patients.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter